2. Search Result
Search Result
Results for "

PL-L2

" in MedChemExpress (MCE) Product Catalog:

3

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99048
    Sintilimab

    IBI308

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer [2] .
    Sintilimab
  • HY-P99048A
    Sintilimab (Anti-PD-1)

    IBI308 (Anti-PD-1)

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer [2] .
    Sintilimab (Anti-PD-1)
  • HY-N9629
    Cyclooctatin

    		Phosphatase Inflammation/Immunology
    Cyclooctatin can inhibit the hemolysis phospholipase [EC 3.1.1.5] (Lyso-PL) activity. Terpentecin as substrates, it inhibits Lyso-PL, PL-A2, PL-C and PL-D with IC50 of 2.9 μg/mL, 65.0 μg/mL, 70.0 μg/mL and >100 μg/mL, respectively .
    Cyclooctatin